Abrocitinib‐A promising option for patients with refractory bullous pemphigoid
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2023/09/09
-
Indian UGC (journal)
-
Refrences10
-
Citations1
-
Weiwei Jiang Department of Dermatology, Tianjin Institute of Integrative Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China ORCID (unauthenticated)
-
Xiuliang Ma Department of Dermatology, Tianjin Institute of Integrative Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China
-
Tao Guo Department of Dermatology, Tianjin Institute of Integrative Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China
-
Mengmeng Song Department of Dermatology, Tianjin Institute of Integrative Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China
-
Junling Zhang Department of Dermatology, Tianjin Institute of Integrative Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital Tianjin China
Cite
Jiang, Weiwei, et al. “Abrocitinib‐A Promising Option for Patients With Refractory Bullous Pemphigoid”. Journal of the European Academy of Dermatology and Venereology, vol. 38, no. 1, 2023, https://doi.org/10.1111/jdv.19475.
Jiang, W., Ma, X., Guo, T., Song, M., & Zhang, J. (2023). Abrocitinib‐A promising option for patients with refractory bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology, 38(1). https://doi.org/10.1111/jdv.19475
Jiang, Weiwei, Xiuliang Ma, Tao Guo, Mengmeng Song, and Junling Zhang. “Abrocitinib‐A Promising Option for Patients With Refractory Bullous Pemphigoid”. Journal of the European Academy of Dermatology and Venereology 38, no. 1 (2023). https://doi.org/10.1111/jdv.19475.
Jiang W, Ma X, Guo T, Song M, Zhang J. Abrocitinib‐A promising option for patients with refractory bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology. 2023;38(1).
Journal Categories
Medicine
Dermatology
Medicine
Medicine (General)
You May Also Like
- Severe Psoriasis – Oral Therapy with a New Retinoid
- Severity Scoring of Atopic Dermatitis: The SCORAD Index
- Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic Dermatitis
- A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab
- Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
Expression of the JAK/STAT Signaling Pathway in Bullous Pemphigoid and Dermatitis Herpetiformis | Mediators of Inflammation |
| 32 | 2017 |
| JAK-inhibitors in dermatology: current evidence and future applications | Journal of Dermatological Treatment |
| 39 | 2018 |
| Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib | JAAD Case Reports | 6 | 2023 | |
| Two cases of bullous pemphigoid effectively treated with oral tofacitinib | JAAD Case Reports | 6 | 2023 | |
| Tofacitinib for refractory ocular mucous membrane pemphigoid | American Journal of Ophthalmology Case Reports | 10 | 2021 |
Citations
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| Dupilumab/methylprednisolone | Reactions Weekly | 2024 |
Citations Analysis
The first research to cite this article was titled Dupilumab/methylprednisolone and was published in 2024. The most recent citation comes from a 2024 study titled Dupilumab/methylprednisolone. This article reached its peak citation in 2024, with 1 citations. It has been cited in 1 different journals. Among related journals, the Reactions Weekly cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.